Business Wire

GABA Resurgence: Pharma Foods International Releases Study Proving Unexpected Benefit to Muscle Growth From a Valued Amino Acid

Share

Pharma Foods International Co. Ltd . has made available for publication its first-ever study proving that supplementing a post-exercise whey protein regimen with their naturally-produced flagship product PharmaGABATM produces an increase in the body’s already existing resting serum growth hormone level, consequently boosting the formation of lean muscle mass. This officially opens a path connecting regular intake of GABA to a naturally beneficial and balanced nutritional profile for the athletic lifestyle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190828005023/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Change in whole body lean mass for 12 wk measured by DXA (Photo: Business Wire)

GABA (γ-Aminobutyric acid) is an amino acid that functions as a key inhibitory neurotransmitter, and is central to cellular activity in the human nervous system. Although GABA’s specific anabolic effect remains undefined, what this study now proves is that oral intake of PharmaGABATM along with whey protein, a known means of stimulating skeletal muscle hypertrophy, enhances the process and produces demonstrably more lean mass than with whey protein alone.

The study looked at 26 males, aged 26 to 48, who practiced progressive-resistance weight training. The group was divided in two — all ingested 10 grams of whey protein daily, half supplemented it with 100 milligrams of PharmaGABATM. The group trained twice weekly, following a systematized circuit of weight-resistance exercises. Resting serum growth hormone was recorded in blood plasma at baseline, four, eight, and twelve weeks; while change in muscle mass was measured using dual-energy X-ray absorptiometry (DXA) at baseline and twelve weeks. The result was that while GH improved significantly for the group ingesting whey protein, the improvement quickly leveled off, whereas the addition of GABA demonstrated proliferation of GH throughout the entire period, and at the end of twelve weeks, lean mass was dramatically increased in the group taking both together.

Pharma Foods International is a leader in the production of GABA, long an admired nutritional supplement for its role in positively affecting such neural functions as relaxation, stress reduction and focus. Its PharmaGABA TM is naturally-derived using lactobacillus hilgardii, used for centuries in the preparation of foods like Korean kimchi. PharmaGABA TM is featured in dozens of products in Japan, reflecting both the public’s confidence in its effectiveness and in the high standard of manufacture that Pharma Foods International has come to represent.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Noriko Tani
info_ingredients@pharmafoods.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Receives Marketing Clearance for Lumipulse ® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 09:58:00 EEST | Press release

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pT

IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes17.5.2025 00:17:00 EEST | Press release

IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050

Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 16:00:00 EEST | Press release

Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy and accessibility to even more consumers. Amazon customers will now be able to discover and purchase Or

The smarter E Europe 2025: Studies, Technologies and Market Trends for the Energy System of Tomorrow16.5.2025 13:47:00 EEST | Press release

Exactly one week has passed since The smarter E Europe closed its doors in Munich. Once again, Europe’s largest alliance of exhibitions for the energy industry turned the Bavarian capital into the epicenter of the global energy sector and impressed with outstanding results. Over the course of three days, 2,737 exhibitors from 57 countries showcased their technologies, business models and market-ready solutions for an intelligent, interconnected and fully renewable energy system. Around 107,000 professionals from 157 nations took the opportunity to connect, initiate partnerships and launch new projects. The accompanying conferences and side events also attracted strong interest, drawing more than 2,600 participants. The message sent out by The smarter E Europe and its four exhibitions – Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe – was clear: We are the energy system. This press release features multimedia. View the full release here: https://www.businesswire.c

IFF Announces Early Tender Results and Increase of Tender Offers for Certain Outstanding Series of Notes16.5.2025 13:30:00 EEST | Press release

IFF (NYSE: IFF) announced today the early tender results for its tender offers to purchase for cash certain of its outstanding series of Notes. IFF also announced it has increased the previously announced Pool 1 Maximum Amount (as defined below) from $1,000,000,000 to $1,100,000,000 (the “Amended Pool 1 Maximum Amount”), the Pool 2 Maximum Amount (as defined below) from $800,000,000 to $900,000,000 (the “Amended Pool 2 Maximum Amount”, and together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), the 2027 Series Tender Cap (as defined below) from $300,000,000 to $400,000,000 and the 2050 Series Tender Cap (as defined below) from $600,000,000 to $649,114,000. The 2025 Notes Series Tender Cap and the 2040 Notes Series Tender Cap (each as defined below) remain unchanged at $500,000,000 and $450,000,000, respectively. Details of tender offers IFF initially offered to purchase for cash: (i) up to $1,000,000,000 aggregate purchase price, excluding accrued and unpaid in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye